Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Mar 17:3:4.
doi: 10.1186/1475-2840-3-4.

Neurohumoral stimulation in type-2-diabetes as an emerging disease concept

Affiliations

Neurohumoral stimulation in type-2-diabetes as an emerging disease concept

R U Pliquett et al. Cardiovasc Diabetol. .

Abstract

Neurohumoral stimulation comprising both autonomic-nervous-system dysfunction and activation of hormonal systems including the renin-angiotensin-aldosterone system (RAAS) was found to be associated with Type-2-diabetes (T2D). Therapeutic strategies such as RAAS interference proved to be beneficial in both T2D treatment and prevention. In addition to an activated RAAS, hyperleptinemia in obesity, hyperinsulinemia in conditions of peripheral insulin resistance and overall oxidative stress in T2D represent known activators of the sympathetic component of the autonomic nervous system. Here, we hypothesize that sympathetic activation may cause peripheral insulin resistance defined as partial blocking of insulin effects on glucose uptake. Resulting hyperinsulinemia or hyperglycemia-related oxidative stress may further aggravate sympatho-excitation. This notion leads to a secondary hypothesis: sympathetic activation worsens from obesity towards insulin resistance, and further towards T2D. In this review, existing evidence relating to neurohumoral stimulation in T2D and consequences thereof, such as oxidative stress and inflammation, are discussed. The aim of this review is to provide a rationale for therapies, which are able to intercept neuroendocrine pathways in T2D and precursor states such as obesity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Relationships between known risk factors for T2D, neurohumoral factors and consequences thereof including oxidative stress and inflammatory response leading to peripheral IR and T2D. Blue arrows represent stimulation pathways, green arrow represents inhibition.
Figure 2
Figure 2
Suggested therapeutic interventions with regard to the framework of T2D risk factors and neurohumoral factors given in Figure 1. Solid lines across empty arrows signify blocked pathways; dotted lines across solid arrows represent attenuated pathways.

References

    1. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819–823. - PubMed
    1. Isnard R, Pousset F, Trochu J, Chafirovskaia O, Carayon A, Golmard J, Lechat P, Thomas D, Bouhour J, Komajda M. Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure. Am J Cardiol. 2000;86:417–421. doi: 10.1016/S0002-9149(00)00957-7. - DOI - PubMed
    1. Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B, Pacher R. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation. 2002;105:2392–2397. doi: 10.1161/01.CIR.0000016642.15031.34. - DOI - PubMed
    1. Rodeheffer RJ, Lerman A, Heublein DM, Burnett JC. Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc. 1992;67:719–724. - PubMed
    1. Carnethon MR, Golden SH, Folsom AR, Haskell W, Liao D. Prospective investigation of autonomic nervous system function and the development of type 2 diabetes: the Atherosclerosis Risk In Communities study, 1987–1998. Circulation. 2003;107:2190–2195. doi: 10.1161/01.CIR.0000066324.74807.95. - DOI - PubMed

LinkOut - more resources